New York University

Janssen Biotech, Inc.

Victor J Torres

Francis Alonzo, Iii

Ashley L Dumont

Anthony S Lynch

Peter T Buckley

Randall J Brezski

Tamara Reyes-Robles

William Strohl

Mark Chiu

Brian Whitaker

Derya Unutmaz

Keri Dorn

Michelle Kinder

Jinquan Luo

Sheng-Jiun Wu

Thomas J Malia

Nathan Majewski

Jeffrey Fernandez

Francis Alonzo

Tanara Reyes-Robles

Francis Alonzo Iii

Francis Iii Alonzo

The present invention relates to methods for treating and preventinginfection and/or a condition resulting from ainfection in a subject that involves administering compositions that inhibitinteraction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.

Cellular factors involved in the cytotoxicity ofleukocidins: novel therapeutic targets

Disclosed herein are isolated and purifiedbi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions orinfection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity ofinfection.

leukocidins, therapeutic compositions, and uses thereof

The disclosure is directed to antibodies that bind tobi-component leukotoxins and/or gamma-hemolysins. Other aspects of the disclosure are directed to pharmaceutical compositions and diagnostic kits containing the leukotoxin and hemolysin antibodies, and therapeutic and diagnostic methods utilizing the leukotoxin and hemolysin antibodies.

Compositions and methods for antibodies targeting staphylococcal leukotoxins

The present invention relates to methods and compositions for preventing and treatingin a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.

Methods of treating and preventinginfections and associated conditions

The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.

Compositions and methods for anti-staphylococcal biologic agents

[object Object]

The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of ainfection, including methicillin-resistant

Compositions and methods for phagocyte delivery of anti-staphylococcal agents

The present invention relates to methods of treating and preventinginfection and/or a condition resulting from ainfection a subject that involves administering a CD11b inhibitor. The present invention further relates to a non-human transgenic animal expressing human CD11b and its use in methods of identifying novel therapeutics for the treatment and prevention ofinfection and/or a condition resulting from ainfection.

Growing community of inventors

New York, NY, United States of America

Victor J Torres